SCHEMBL4516684

SCHEMBL4516684

Cc1cc(C)c(S(=O)(=O)NCCNc2ccccc2)c(C)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.67
NR3C1 P04150 4/20 0.60
PGR P06401 3/20 0.60
NR3C2 P08235 3/20 0.60
FABP4 P15090 1/20 0.54
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
MAPT P10636 4/20 0.52
GAA P10253 2/20 0.52
FGB P02675 1/20 0.52
POLB P06746 1/20 0.52
ALOX12 P18054 1/20 0.48
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2C19 P33261 2/20 0.48
MAPK1 P28482 1/20 0.48
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NR2F2 P24468 1/20 0.48
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4448257 0.91 L3MBTL1 (0.63) L3MBTL1NR3C1PGRNR3C2FABP4
SCHEMBL19499893 0.89 L3MBTL1 (0.56) L3MBTL1NR3C1PGRNR3C2FABP4
SCHEMBL5562243 0.83 L3MBTL1 (0.67) L3MBTL1FABP4MEN1KMT2AMAPT
SCHEMBL17847425 0.80 L3MBTL1 (1.00) L3MBTL1NR3C1FABP4MEN1KMT2A
SCHEMBL4516501 0.80 F2 (0.55) L3MBTL1NR3C1PGRNR3C2MEN1
SCHEMBL19500035 0.79 L3MBTL1 (0.56) L3MBTL1NR3C1FABP4MEN1KMT2A
SCHEMBL7095970 0.78 MEN1 (0.68) L3MBTL1MEN1KMT2AMAPTGAA
SCHEMBL4514428 0.78 L3MBTL1 (0.83) L3MBTL1NR3C1FABP4MEN1KMT2A
SCHEMBL812919 0.77 TSHR (0.70) L3MBTL1NR3C1PGRNR3C2MEN1
SCHEMBL5963342 0.77 FABP4 (0.76) L3MBTL1FABP4MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
EP-1807391-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AstraZeneca AB (SE) 2007-07-18 EP disclosed
WO-2006046916-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES ASTRAZENECA AB (SE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 L3MBTL1 4844/4885NR3C1 1/4885PGR 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.